Catalyst
Slingshot members are tracking this event:
Resubmitted New Drug Application for AstraZeneca's (AZN) ZS-9 in Hyperkalemia Accepted for Review by FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Resubmitted, New Drug Application, Zs-9, Hyperkalemia, Fda, Accepted
